The challenge of pharmacological thromboprophylaxis in ICU patients: anti-FXa activity does not constitute the simple solution. Author's reply.
作者信息
Hofmaenner Daniel A, Singer Mervyn
机构信息
Bloomsbury Institute of Intensive Care Medicine, Division of Medicine, University College London, Cruciform Building, Gower St, London, WC1E 6BT, UK.
出版信息
Intensive Care Med. 2022 Aug;48(8):1118-1119. doi: 10.1007/s00134-022-06768-0. Epub 2022 Jun 17.
Abstract
摘要
相似文献
1
The challenge of pharmacological thromboprophylaxis in ICU patients: anti-FXa activity does not constitute the simple solution. Author's reply.
Intensive Care Med. 2022 Aug;48(8):1118-1119. doi: 10.1007/s00134-022-06768-0. Epub 2022 Jun 17.
2
The challenge of pharmacological thromboprophylaxis in ICU patients: anti-FXa activity does not constitute a simple solution.
Intensive Care Med. 2022 Aug;48(8):1116-1117. doi: 10.1007/s00134-022-06744-8. Epub 2022 May 25.
3
Plasma anti-FXa level as a surrogate marker of the adequacy of thromboprophylaxis in critically ill patients: A systematic review.
Thromb Res. 2016 Mar;139:10-6. doi: 10.1016/j.thromres.2015.12.016. Epub 2016 Jan 4.
4
The Effectiveness of the Intermediate and Therapeutic Doses of Enoxaparin in COVID-19 Patients: A Comparative Study of Factor Xa Inhibition.
Acta Haematol. 2023;146(2):137-143. doi: 10.1159/000528736. Epub 2022 Dec 20.
5
Bioactivity of enoxaparin in critically ill patients with normal renal function.
Br J Clin Pharmacol. 2012 Nov;74(5):806-14. doi: 10.1111/j.1365-2125.2012.04285.x.
6
Low molecular weight heparin for venous thromboembolism prophylaxis in general Intensive Care Unit patients: an anti-factor Xa level-based approach.
Minerva Anestesiol. 2023 May;89(5):425-433. doi: 10.23736/S0375-9393.22.16920-8. Epub 2022 Nov 3.
7
Factor Xa inhibitors in acute coronary syndromes and venous thromboembolism.
Curr Vasc Pharmacol. 2010 Jan;8(1):5-11. doi: 10.2174/157016110790226688.
8
Inadequate prophylactic effect of low-molecular weight heparin in critically ill COVID-19 patients.
J Crit Care. 2020 Dec;60:249-252. doi: 10.1016/j.jcrc.2020.08.026. Epub 2020 Sep 3.
9
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Cochrane Database Syst Rev. 2020 Dec 18;12(12):CD008500. doi: 10.1002/14651858.CD008500.pub5.
10
Oral direct factor Xa inhibitor versus enoxaparin for thromboprophylaxis after hip or knee arthroplasty: Systemic review, traditional meta-analysis, dose-response meta-analysis and network meta-analysis.
Thromb Res. 2015 Dec;136(6):1133-44. doi: 10.1016/j.thromres.2015.10.009. Epub 2015 Oct 20.
引用本文的文献
1
A retrospective multicenter cohort study of the association between anti-Factor Xa values and death, thromboembolism, and bleeding in patients with critical COVID-19.
Thromb J. 2023 Oct 2;21(1):101. doi: 10.1186/s12959-023-00541-z.
本文引用的文献
1
Anti-factor Xa Activity Is Not Associated With Venous Thromboembolism in Critically Ill Patients Receiving Enoxaparin for Thromboprophylaxis: A Retrospective Observational Study.
Front Med (Lausanne). 2022 Apr 29;9:888451. doi: 10.3389/fmed.2022.888451. eCollection 2022.
2
Challenging management dogma where evidence is non-existent, weak or outdated.
Intensive Care Med. 2022 May;48(5):548-558. doi: 10.1007/s00134-022-06659-4. Epub 2022 Mar 18.
3
Anticoagulants for people hospitalised with COVID-19.
Cochrane Database Syst Rev. 2022 Mar 4;3(3):CD013739. doi: 10.1002/14651858.CD013739.pub2.
4
VTE Prophylaxis in Critically Ill Adults: A Systematic Review and Network Meta-analysis.
Chest. 2022 Feb;161(2):418-428. doi: 10.1016/j.chest.2021.08.050. Epub 2021 Aug 19.
5
Meta-analysis: travel and risk for venous thromboembolism.
Ann Intern Med. 2009 Aug 4;151(3):180-90. doi: 10.7326/0003-4819-151-3-200908040-00129. Epub 2009 Jul 6.
Zotero 插件